Intelligence Profile
Research Papers
Recaticimab is a novel monoclonal antibody engineered to enhance lipid-lowering effects by targeting PCSK9, an enzyme that influences cholesterol levels.
A 2025 study published in Biomedical and Environmental Sciences evaluated the impact of Recaticimab on hyperlipidemia and plasma glucose in a randomized, double-blind, placebo-controlled Phase 1b/2 trial. The study indicated that Recaticimab effectively reduces LDL cholesterol levels with a favorable safety profile.
In the Phase 3 REMAIN-3 trial, detailed in Cardiovascular Research (2025), Recaticimab was assessed in patients with heterozygous familial hypercholesterolemia. This multicenter, double-blind, placebo-controlled study demonstrated significant LDL cholesterol reduction over the trial period.
A systematic review and meta-analysis published in Pharmacotherapy (2026) evaluated multiple randomized controlled trials to assess Recaticimab's efficacy and safety. The analysis highlighted its consistent cholesterol-lowering effects and manageable side effects.
Further, a network meta-analysis in Cardiovascular Therapeutics explored four PCSK9 monoclonal antibodies, including Recaticimab, reaffirming its efficacy in reducing cholesterol levels.
Population pharmacokinetics and dynamics modeling, reported in Clinical Pharmacokinetics (2025), suggested predictable behavior of Recaticimab in both healthy volunteers and hypercholesterolemia patients, supporting its clinical use.
Overall, Recaticimab shows promising potential in treating hypercholesterolemia, backed by multiple trials confirming its safety and efficacy. However, evidence is still emerging, and further long-term studies are warranted to fully establish its clinical benefits.
Disclaimer: This information is for educational purposes only and not a substitute for professional medical advice.